BioSapien doses first patient in MediChip cancer-implant trial in Abu Dhabi
What's the deal? BioSapien, a clinical-stage biotech and Hub71 startup, has dosed the first patient in its Phase I trial of MediChip-5-FU at Burjeel Cancer Institute in Abu Dhabi. It marks the first time the implant has been administered in a human.
What is MediChip? It is a biodegradable, 3D-printed implant that delivers 5-fluorouracil (5-FU), a common chemotherapy drug, directly at the tumour site through controlled local release. The design aims to concentrate the drug where needed while limiting exposure to healthy tissue.
What's the endgame? The study, called OPTIMISE-REFORM, is evaluating the implant in patients with localised rectal cancer, focusing first on safety and tolerability. Longer term, BioSapien wants to test whether localised chemotherapy could support organ-preserving treatment and reduce the need for major surgery.
Why now? The dosing follows the opening of the world's first MediChip clinical site at Burjeel Cancer Institute earlier this month. It caps years of product development, manufacturing preparation, analytical testing, and regulatory and ethics review.
"Today, MediChip moves from years of development into human clinical evaluation. That is what we have been building toward," said Khatija Ali, founder and chief executive officer of BioSapien.
Mohammad Adileh, director of the Surgical Oncology Division at Burjeel Cancer Institute, leads the clinical evaluation as principal investigator. The trial will generate initial human safety data to guide MediChip's further development.
The signal: BioSapien's progress positions Abu Dhabi, through its Hub71 ecosystem, as a venue for advancing experimental healthcare technologies from lab to clinic. Whether localised chemotherapy delivers on its promise now rests on trial results still to come.
Read more: hub71.com
Image credit: NavyMedicine
